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Andrew Boulle, Matthias Egger, Harry Moultrie, for the International epidemiologic Databases to Evaluate AIDS Southern 
Africa (IeDEA-SA) collaboration 
South Africa’s paediatric antiretroviral treatment (ART) 
programme is the largest in the world, with an estimated 
32 000 children <15 years of age on treatment at the end of 
2007.1 Nevertheless the programme reaches less than half 
of the children estimated to need ART according to national 
guidelines,2 and an even lower proportion if need is defined 
using revised 2008 World Health Organization (WHO) 
guidelines for early treatment of HIV-infected infants.3
Despite the size of the national programme, few individual 
cohorts have published treatment outcomes, with follow-up 
limited to 1 year.4-6 Similar to other African countries, these 
cohorts have demonstrated good short-term outcomes.7,8 
However, the small size of any individual South African cohort 
has limited statistical power to robustly describe associations 
with mortality for all markers of disease severity.9-14 
Furthermore, the lack of routinely collected national 
monitoring data means that South Africa has lagged behind 
other southern African countries in publishing programme 
outcomes, and more importantly, has no mechanism to assess 
the effectiveness of this enormous health service 
intervention.9,15 South Africa could potentially generate 
valuable paediatric ART data, not only because of the size of 
the programme but also due to the uniform approach to 
treatment shaped by national guidelines, as well as good access 
to laboratory testing facilities, particularly viral load. 
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Objectives. To assess paediatric antiretroviral treatment (ART) 
outcomes and their associations from a collaborative cohort 
representing 20% of the South African national treatment 
programme.
Design and setting. Multi-cohort study of 7 public sector 
paediatric ART programmes in Gauteng, Western Cape and 
KwaZulu-Natal provinces.
Subjects. ART-naïve children (≤16 years) who commenced 
treatment with ≥3 antiretroviral drugs before March 2008.
Outcome measures. Time to death or loss to follow-up were 
assessed using the Kaplan-Meier method. Associations 
between baseline characteristics and mortality were assessed 
with Cox proportional hazards models stratified by site. 
Immune status, virological suppression and growth were 
described in relation to duration of ART. 
Results. The median (interquartile range) age of 6 078 children 
with 9 368 child-years of follow-up was 43 (15 - 83) months, 
with 29% being <18 months. Most were severely ill at ART 
initiation. More than 75% of children were appropriately 
monitored at 6-monthly intervals with viral load suppression 
(<400 copies/ml) being 80% or above throughout 36 months 
of treatment. Mortality and retention in care at 3 years were 
7.7% (95% confidence interval 7.0 - 8.6%) and 81.4% (80.1 - 
82.6%), respectively. Together with young age, all markers of 
disease severity (low weight-for-age z-score, high viral load, 
severe immune suppression, stage 3/4 disease and anaemia) 
were independently associated with mortality.
Conclusions. Dramatic clinical benefit for children accessing 
the national ART programme is demonstrated. Higher 
mortality in infants and those with advanced disease 
highlights the need for early diagnosis of HIV infection and 
commencement of ART. 
S Afr Med J 2009; 99: 730-737.
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The International epidemiologic Databases to Evaluate AIDS 
(IeDEA) Southern Africa Collaboration includes 8 sites in South 
Africa providing paediatric ART at different levels of care in 3 
provinces. More than 6 000 children had commenced ART at 
these sites by the end of 2007, representing >20% of children 
in the national programme at that time. This collaboration 
therefore provides a unique opportunity to examine the 
effectiveness of the South African paediatric ART programme 
and the extent to which national guidelines are being followed.
Our objectives were to describe for this combined cohort the 
outcomes of children receiving ART, factors associated with 
these outcomes, and the extent to which national programme 
guidelines are being followed. 
Methods
Study, design, setting and population
Data for this cohort analysis were collected prospectively at 
sites and transferred anonymously to the IeDEA data centre in 
a standard format between May 2007 and February 2008. Each 
site has institutional ethical approval for contribution of data to 
IeDEA collaborative analyses. 
HIV-infected, ART-naïve children with known gender 
and date of birth who initiated treatment with at least 3 
antiretroviral drugs at age ≤16 years on a documented date 
between 1 June 1999 and 29 February 2008 were included. Sites 
where less than 25 children met these criteria were excluded. 
Key variables
Information describing ART programmes was provided on 
standardised questionnaires by site representatives. Child 
characteristics included measures of disease severity (WHO 
stage, weight, height, haemoglobin (Hb), CD4 percentage or 
count, viral load) at ART initiation and at 6-monthly follow-up 
intervals, together with initiating regimen. CD4 percentage 
and absolute counts are reported, with the worst of these 
being used to determine whether the child was severely 
immunosuppressed according to WHO criteria.16 Primary 
caregiver and exposure to prevention of mother-to-child 
transmission (PMTCT) regimens were recorded. 
As sites changed from the WHO 3-stage to WHO 4-stage 
classification of disease severity during the latter half of 2004, 
all children with stage 3 or 4 disease under either system were 
considered to have clinically advanced disease.17 Viral loads 
and CD4 counts were performed by local laboratories using 
standard methods. A viral load <400 copies/ml was considered 
undetectable. Sex- and age-standardised z-scores for weight 
and height were calculated for children ≤10 years at time of 
measurement using WHO 2007 growth reference standards.18
Sites provided data on known deaths and transfers out 
(TFO). Children were deemed lost to follow-up (LFU) if the last 
visit date was more than 6 months before date of closure of the 
site database, with the last visit date used as date of LFU. 
Analysis
Kaplan-Meier estimates of mortality, LFU and TFO were 
determined. Cox proportional hazards models stratified 
by site were used to assess associations between baseline 
characteristics and mortality. Multivariate models were built by 
sequentially adding the next most significant predictor variable 
from univariate analysis, and variables with a p-value <0.1 after 
adjustment for those already in the model, or that changed the 
hazard ratio (HR) for variables in the model by more than 10%, 
were retained. Separate models were generated excluding the 
weight-for-age z-score (WAZs) as this could only be calculated 
for children ≤10 years of age, and viral load, as this is not 
routinely available in most resource-limited settings. Since Hb 
at ART initiation was only available for a third of children, this 
was excluded from the main model, but a separate model was 
generated to assess the effect of anaemia on mortality. Age was 
categorised as <12 months, 12 - 35 months and ≥36 months. 
WAZs were categorised as <–3, –3 to –2 and ≥–2, according to 
United Nations Children’s Fund (UNICEF) definitions.19  Viral 
load was categorised as ≤100 000, 100 000 to 1 million and >1 
million copies/ml, and year of starting ART as ≤2005 and ≥2006 
as these thresholds explained the largest amount of variability 
in mortality. Anaemia was defined as Hb <8 g/dl. 
As these data include a substantial proportion of children 
who received ART through donor-funded programmes before 
commencement of National Department of Health provision 
on 1 April 2004, a sensitivity analysis was performed on 
descriptions of baseline characteristics and survival models 
with data limited to those children who started ART after 31 
March 2004. All statistical analyses were performed using Stata 
version 10 (STATA Corporation, College Station, TX).
Results
Exclusions
Of the 8 South African IeDEA sites, 1 was excluded because the 
cohort comprised <25 children. The remaining data included 
6 266 children on ART. Of these, 85 did not meet inclusion 
criteria due to missing or inconsistent baseline data. Non-naïve 
patients (N=39) and those commenced on <3 drugs (N=64) 
were excluded. The final data-set therefore comprised 6 078 
children (49.1% female) from 7 sites with 9 368 child-years of 
follow-up, and median (interquartile range (IQR)) follow-up 
duration of 16 (6 - 29) months.
Contributing sites
Site characteristics are shown in Table I. Of note, sites are all 
urban and represent major centres in 3 provinces (Western 
Cape, Gauteng and KwaZulu-Natal); however, all levels of care 
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are represented. There is a wide variation in the number of 
children being treated with ART at different sites, from  
>2 000 at a site providing all levels of care in Gauteng to <300 
at a smaller primary care clinic in Cape Town. The median age 
of children from tertiary care sites is less than that of children 
from sites providing other levels of care (18.4 v. 51.9 months; 
p<0.0001).
Characteristics at ART start
Most children were severely ill with advanced clinical disease, 
immunosuppression, high viral load and impaired growth at 
the start of ART (Table II). The median (IQR) age of children 
commencing ART was 42.7 (14.7 - 82.5) months, with nearly 
30% of children less than 18 months of age. The starting 
regimen included stavudine (d4T) and lamivudine (3TC) with 
either efavirenz or lopinavir/ritonavir (Kaletra) as the third 
drug for 81% of children. 
Data were incomplete for many key variables. In particular, 
WHO stage was unknown for nearly a third of children, while 
caregiver and PMTCT exposure information was provided by 
only a few sites at which exposure status was still unknown 
for nearly 50%. Characteristics at start of ART were not 
substantially different when the data were limited to those 
initiating treatment after formal commencement of the national 
programme (N=5 601, results not shown).
Survival and retention in care
Mortality at 3 years was 7.7% (95% confidence interval (CI) 7.0 
- 8.6%), and 81.4% (95% CI 80.1 - 82.6%) of children were alive 
and in care at 3 years (Fig. 1, a, b). There was rapid transfer 
from sites providing exclusively tertiary care to lower levels 
after the first 6 months of ART, with the tertiary cohort reduced 
by nearly 50% at 2 years (Fig. 1, c). LFU at 1 year increased 
from 2.2% (95% CI 1.1 - 4.7%) in those who commenced 
ART before 2004 to 8.2% (95% CI 7.1 - 9.4%) in those who 
commenced during or after 2006.
Mortality was higher for younger children, those with 
more advanced disease and those who were more severely 
immunosuppressed (Fig. 1). All markers of disease severity 
were independent predictors of mortality in multivariate 
analysis (Table III). Use of a protease inhibitor versus a non-
nucleoside reverse transcriptase inhibitor as the third drug 
had no effect on mortality (p=0.572). Similarly, Hb <8 g/dl 
independently predicts mortality after adjustment for disease 
severity, age and programme year (adjusted hazard ratio 
1.65; 95% CI 1.07 - 2.55%; p=0.024). Models excluding WAZ 
and viral load as predictors yielded similar results to the full 
model, as did models limited to those children treated after 
commencement of the national programme (results not shown). 
Table I. Characteristics of facilities providing ART
           Median (IQR)  Number of
      Main level                  No. of  age (mo.) of children (%) 
Cohort name      of care  Type of clinic   Target              First year of            children children at <1 yr of age
and location     provided and payment  population         ART provision         on ART ART initiation at ART initiation
Harriet Shezi Clinic,    All levels Public and       2001             2 183        55.9  328 (15.0)
Soweto    research, free ART  Children only       (21.9 - 90.3)
Rahima Moosa,     All levels Public, free ART  Children and     1999             1 023        44.0  202 (19.8)
Mother and      pregnant women       (15.9 - 84.4)
Child Hospital
Johannesburg
Red Cross Children’s   Tertiary Public and   Children only    2001             839        16.1  351 (41.8)
Hospital, Cape Town  research, free ART         (6.3 - 50.2)
Tygerberg Hospital,     Tertiary Public and,  Adults and    2000             690        21.6  240 (34.8)
Cape Town   research free ART  children, separate      (8.5 - 59.0)
       clinics
Khayelitsha     Primary Public, free ART  Adults and     2001             650        41.7  94 (14.5)
Community Health       children, separate      (20.3 - 74.2)
Centre, Cape Town      clinics
Gugulethu      Primary Public and,  Adults and    2001             262        47.1  42 (16.0)
Community Health   research free ART  chil dren, separate       (18.3 - 82.4)
Centre, Cape Town      clinics
McCord Hospital,      Secondary Government-
Durban     subsidised mission   Adults and    2003             431        72.4  33 (7.7)
    hospital, small co-  children, separate      (33.0 - 109.2) 
    payment   clinics
   Total                     6 078
Table II. Characteristics of children at ART initiation (N=6 078)
Year of ART start (%)
≤2003         321 (5.3)
2004         1 076 (17.7)
2005         1 809 (29.8)
2006         1 707 (28.1)
≥2007         1 165 (19.2)
Female (%)        2 981 (49.1)
Age
Median (IQR) age (mo.)       42.7 (14.7 - 82.5)
Less than 18 mo. (%)       1 758 (28.9)
WHO stage (%) 
1         263 (4.3)
2         745 (12.3)
3/4         3 073 (50.1)
WHO stage unknown       1 997 (32.9)
PMTCT exposure (%) (N=4 695)*
Known exposed        596 (12.7)
Known unexposed       1 764 (37.6)
Exposure status unknown       2 335 (49.7)
Primary caregiver (%) (N=4 045)†
Mother         2 449 (60.5)
Father         141 (3.5)
Grandmother        204 (5.0)
Other family        712 (17.6)
Other         123 (3.0)
Institution        225 (5.6)
Unknown        191 (4.7)
Laboratory measurements
Median (IQR) CD4% by age group (N=4 592)
≤11 mo. (N=1 045)       16.4 (10.0 - 23.6)
12 - 35 mo. (N=1 089)       13.0 (9.0 - 18.1)
36 - 59 mo. (N=712)       12.0 (7.2 - 16.5)
≥5 yrs (N=1 746)       10.0 (4.7 - 15.0)
Median (IQR) CD4 absolute count (cells/µl) by age group (N=4 852)
≤11 mo. (N=1 062)       642 (280 - 1 132)
12 - 35 mo.  (N=1 145)       636 (345 - 1 014)
36 - 59 mo. (N=750)       437 (251 - 691)
≥5 yrs (N=1 895)       435 (81 - 241)
Severely immunosuppressed (%) (N=4 934)‡     4 024 (81.6)
Median (IQR) log viral load (N=4 063)     5.36 (4.74 - 5.89)
Viral load >1million copies/ml (%) (N=4 063)     850 (20.9)
Haemoglobin <8 g/dl (%) (N=1 803)      220 (12.2)
Anthropometry§ 
z-scores 
Median (IQR) weight-for-age z-score (N=3 892)    –1.89 (–3.20 - –0.93)
Median (IQR) height-for-age z-score (N= 3 690)    –2.39 (–3.37 - –1.44)
Median (IQR) weight-for-height z-score (N=3 186)    –0.46 (–1.73 - 0.55)
Weight-for-age z-scores (N=3 892)
–3 - –2 (%)        747 (19.1)
<–3 (%)        1 096 (28.2)
Height-for-age z-score (N=3 690) 
–3 - –2 (%)        1 011 (27.4)
<–3 (%)        1 242 (33.7)
Weight-for-height z-score (N=3 186) 
–3 - –2 (%)        312 (9.8)
<–3 (%)        365 (11.5)
Regimen (%) (N=5 484)
Most common regimens
d4T+3TC+efavirenz       2 839 (51.8)
d4T+3TC+lopinavir/ritonavir¶      1 603 (29.2)
First NRTI
d4T-based regimen       4 856 (88.5)
Third drug
Lopinavir/ritonavir-based regimenıı     1 808 (33.0)
Ritonavir-based regimen       191 (3.5)
Regimen not recorded       594
*Data only available for Rahima Moosa, Harriet Shezi, Khayelitsha and Red Cross. 
†Data only available for Rahima Moosa, Harriet Shezi and Red Cross; for Harriet Shezi caregiver information was collected at first visit – may be different from caregiver at ART start.
‡WHO criteria for severe immune suppression (CD4% <25 or CD4 count <1 500/µl if age ≤11months; CD4% <20 or CD4 count <750/µl if age between 12 and 35 months; CD4% <15 or 
CD4 count <350/µl if age between 36 and 59 months; CD4% <15 or CD4 count <200/µl if age ≥60 months. 
§Only calculated for children ≤120 months (N=5 535).
¶Includes 201 children with additional ritonavir boosting. 
ııIncludes 214 children with additional ritonavir boosting.
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Monitoring of viral and immune response to 
treatment
Follow-up measurements of CD4 and viral load are shown 
in Fig. 2. Notably, measurements of CD4 and viral load at 
6-monthly intervals were available for over 80% and 75% of 
children respectively through to 36 months, with ≥80% of 
children virologically suppressed throughout (82.4% at 3 years; 
95% CI 79.4 - 85.5%). The percentage (95% CI) of children 
severely immunosuppressed at 1 and 3 years dropped to 16.9% 
(15.4 - 18.3%) and 6.4% (4.2 - 8.6%), respectively.
Growth response to treatment
There was initial rapid weight gain from a median WAZ of 
–1.80 to –0.75 by 12 months, remaining relatively constant 
thereafter (Fig. 3). Height increased more slowly but was still 
increasing at 36 months, 
when a quarter of children 
still had a height-for-age z-
score <–2. 
Discussion
Main findings of the 
study
Outcomes of this cohort 
of ART-treated children in 
South Africa, the largest 
from a single country in 
Africa to date, were good 
with mortality of 7.7% and 
81.1% of children alive and in 
care at 3 years. As expected, 
young age together with all 
markers of disease severity 
were independent predictors 
of mortality. These findings 
are strikingly similar to those 
of a similar combined cohort 
analysis of sub-Saharan 
paediatric ART programmes, 
the Kids’ Antiretroviral 
Treatment in Lower-Incomes 
Countries (KIDS-ART-LINC) 
Collaboration.8 Furthermore, 
follow-up monitoring of 
laboratory parameters was 
excellent, with more than 
75% of children tested 
6-monthly according 
to national guidelines. 
Although comparisons with 
rich countries are difficult 
owing to the older age of ART 
commencement in the South African children and inherent 
survival bias, the high level of virological suppression is 
encouraging and compares favourably with cohorts from 
Europe20 and North America21 and other African studies.7,14 
Similarly, children remaining in care experienced dramatic 
improvements in growth and immune status. While the 
proportion and absolute number of nearly 2 000 very young 
children accessing ART are much greater than in most other 
African studies, across the country older children are still 
preferentially accessing treatment with more than 70% of the 
cohort being over 18 months of age.7,8,22 
Strengths and generalisablity of findings
This study is valuable because of the large number of children 
and length of follow-up, but particularly because of the high 
Fig. 1. Kaplan-Meier estimates for outcomes of (a) death, (b) death and loss to follow-up, and (c) transfer out. Kaplan-
Meier estimates of mortality by (d) age group, (e) degree of immunosuppression and (f) WHO clinical stage.
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absolute number of those under 18 months of age. With new 
WHO guidelines encouraging early ART initiation in infants, 
a better understanding of clinical outcomes in this age group 
is required.3 In addition, the availability of regular viral load 
information is unusual in the African context. Inclusion 
of children from a number of different sites in 3 provinces 
and at different levels of care enhances representivity, while 
uniformity of treatment protocols lends itself to collation into a 
single analysis.
Limitations
Although the study includes some of the busiest routine 
public sector clinics, it should be acknowledged that 
IeDEA collaboration sites must have capacity for electronic 
collection of routine data, which is not the norm. Some high-
burden provinces are not included in the study, and there 
is disproportionate representation of sites with tertiary care 
capacity. The thorough monitoring and high number of infants 
on ART therefore probably represent best-practice examples in 
well-resourced clinics.
While LFU in this study is relatively low compared with 
adult publications of routine cohort data,23 there is variation 
in LFU at different sites. This is of concern as many of those 
who are LFU are likely to have died, resulting in under-
ascertainment of mortality. Indeed, while there are various 
plausible explanations for the apparent protective effect on 
mortality of starting ART after 2005 (including that children 
starting earlier are ‘sicker’ in ways not captured by markers of 
disease severity available for this analysis), the contribution of 
increasing LFU in later years as programmes expand should 
not be underestimated. In this respect, the effect of choice of 
first drug (zidovudine v. stavudine) on mortality could not be 
definitively assessed owing to changes in prescribing patterns 
after the introduction of national treatment guidelines in 2004 
and increasing LFU over time. The high transfer rate from 
tertiary sites to lower levels of care limits duration of follow-up 
for these patients. Systems of data collection integrated across 
sites are needed to ascertain outcomes for transferred patients. 
Poor integration of health information systems is also 
reflected in the paucity of PMTCT exposure data. This reflects 
poor integration of antenatal, routine child care and HIV 
services themselves within the health system, a major barrier 
to timeous HIV diagnosis and referral for care of those infants 
infected despite PMTCT exposure.7,22,24 Completeness and 
accuracy of other exposure variables is also limited, while 
historical changes in the WHO staging system limit its value as 
a measure of disease advancement.
Reflections on the South African national paediatric 
ART programme
This study indicates that the programme is successful for 
those children who access it. The latter caveat is important, as 
the fact that 20% of all children are treated at a handful of 
sites, all in large urban centres, suggests that considerable 
inequities in access are likely. Nevertheless the fastidious 
monitoring, utilisation of first-line regimens recommended 
in national guidelines, good survival, high proportions of 
children with viral suppression and favourable immune and 
growth responses – at least at these sites – are encouraging. 
The Western Cape has the specific aim of treating children at 
their nearest health centre whenever possible, with only those 
warranting specialist care remaining at tertiary facilities.24 
Table III. Predictors of mortality using Cox-proportional hazards model stratified by site (adjusted for year of ART start)
           Adjusted HR
           Full model
Characteristic at ART start        Crude HR        95% CI     p-value    (N=2 449) 95% CI         p-value
WAZ           <0.001*             <0.001*
>–2                1                1
–3 - –2           1.93       1.29 - 2.89         1.13  0.69 - 1.87 
< –3           5.23       3.84 - 7.12         2.44  1.65 - 3.59 
Viral load (copies/ml)         <0.001*              0.010*
<100 000               1                 1
100 000 to 1 million         1.75       1.24 - 2.45         1.68  1.02 - 2.76 
>1 million          3.30       2.32 - 4.70         2.22  1.31 - 3.77 
Severe immunosuppression 
(WHO definition)          4.23      2.55 - 7.00      <0.001        3.83  1.68 - 8.72            0.001
WHO stage 3 or 4 (v. 1 or 2)          3.01      2.00 - 4.54      <0.001        2.16  1.28 - 3.62            0.004
Age            <0.001*                0.002*
>3 yrs               1                 1
1 - 3 yrs          1.31      0.98 - 1.74         1.17  0.76 - 1.84 
<1 yr           3.38       2.65 - 4.31         2.00  1.30 - 3.07 
ART commenced before 2006         1.28      1.02 - 1.60        0.036        1.68  1.18 - 2.39            0.004
p-values derived from likelihood ratio tests.
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In this respect, the rapid 
transfer of children from 
exclusive tertiary to primary 
care sites, together with the 
difference in ages of children 
starting ART at different 
levels of care, indicate that 
children are indeed receiving 
care at the appropriate level.
Although the cohort 
includes several infants, 
the number is negligible 
compared with the estimated 
64 000 new infections 
that occur perinatally and 
through breastfeeding every 
year.25 Together with lack 
of integration of antenatal 
PMTCT and paediatric HIV 
services, perceived and 
actual lack of expertise in the 
care of young HIV-infected 
infants pose significant 
barriers to access for infants, who are still 
largely cared for at tertiary sites. These 
problems need to be addressed urgently if 
South Africa seeks to implement revised 
WHO guidelines recommending early ART 
for infants irrespective of disease severity.3 
In this respect it should be noted that 
the relatively poor outcomes for infants 
in this study would not necessarily be the 
scenario should infant ART initiation be 
prioritised. Disease progression is rapid 
in HIV-infected infants, and in this study 
children commencing ART at a young 
age are those whose disease progressed 
rapidly enough to meet previous WHO 
disease severity criteria while they were 
still young and who were able to access 
treatment before otherwise inevitable early 
death.26 Better outcomes for older children 
represent a survivor effect, with older age 
at ART initiation being a proxy for slower 
disease progression. In contrast, other 
South African studies have shown excellent 
outcomes for infants commencing ART 
before disease progression.27,28 
Conclusion
This study of a substantial proportion of 
the South African national ART programme 
for children demonstrates the dramatic 
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Fig. 3. Growth response to ART (only includes children with measurement at ART start and at least 
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*z-scores only calculated for children <10 years at time of measurement.
†
Only includes children with measurement at ART start and at least one follow-up measurement.
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clinical benefit for those accessing the programme. The higher 
mortality in infants and young children and those with 
advanced disease highlights the need to identify HIV-infected 
infants and commence ART before disease progression.
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